⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IRWD News
Ironwood Pharmaceuticals, Inc. - Class A
Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to the Launch of Novel GLP-2 Analogues | DelveInsight
prnewswire.com
IRWD
ZPH
TAK
JAGX
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
businesswire.com
IRWD